RU99103623A - ANTI-THROMBOTIC AND ANTI-ATEROGENIC PHARMACEUTICAL COMPOSITION CONTAINING TIENPYRIDINE DERIVATIVE AND HMG-COA-REDUCTASE INHIBITOR - Google Patents
ANTI-THROMBOTIC AND ANTI-ATEROGENIC PHARMACEUTICAL COMPOSITION CONTAINING TIENPYRIDINE DERIVATIVE AND HMG-COA-REDUCTASE INHIBITORInfo
- Publication number
- RU99103623A RU99103623A RU99103623/14A RU99103623A RU99103623A RU 99103623 A RU99103623 A RU 99103623A RU 99103623/14 A RU99103623/14 A RU 99103623/14A RU 99103623 A RU99103623 A RU 99103623A RU 99103623 A RU99103623 A RU 99103623A
- Authority
- RU
- Russia
- Prior art keywords
- hydrogen
- formula
- composition according
- group
- alkyl
- Prior art date
Links
- 239000003146 anticoagulant agent Substances 0.000 title claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title claims 2
- 239000008194 pharmaceutical composition Substances 0.000 title claims 2
- 230000002785 anti-thrombosis Effects 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- 150000001875 compounds Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 8
- 239000011780 sodium chloride Substances 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 5
- 229960001495 Pravastatin Sodium Drugs 0.000 claims 5
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 5
- 239000011737 fluorine Substances 0.000 claims 5
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 5
- VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 claims 5
- 229960002855 simvastatin Drugs 0.000 claims 5
- 229960002961 Ticlopidine Hydrochloride Drugs 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 239000000460 chlorine Substances 0.000 claims 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 4
- 125000000422 delta-lactone group Chemical group 0.000 claims 4
- MTKNGOHFNXIVOS-UHFFFAOYSA-N ticlopidine hydrochloride Chemical group [H+].[Cl-].ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 MTKNGOHFNXIVOS-UHFFFAOYSA-N 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 229950010477 clopidogrel hydrogen sulphate Drugs 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 150000002475 indoles Chemical class 0.000 claims 3
- 150000003536 tetrazoles Chemical class 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- -1 1,3-propylene Chemical group 0.000 claims 2
- 102000004316 Oxidoreductases Human genes 0.000 claims 2
- 108090000854 Oxidoreductases Proteins 0.000 claims 2
- FDEODCTUSIWGLK-RSAXXLAASA-N clopidogrel sulfate Chemical compound [H+].OS([O-])(=O)=O.C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl FDEODCTUSIWGLK-RSAXXLAASA-N 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- ZLRFPQPVXRIBCQ-UHFFFAOYSA-N 2-$l^{1}-oxidanyl-2-methylpropane Chemical group CC(C)(C)[O] ZLRFPQPVXRIBCQ-UHFFFAOYSA-N 0.000 claims 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N Cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- AJLFOPYRIVGYMJ-INTXDZFKSA-N Mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims 1
- 229950009116 Mevastatin Drugs 0.000 claims 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N Propadiene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 230000000489 anti-atherogenic Effects 0.000 claims 1
- 230000000702 anti-platelet Effects 0.000 claims 1
- 229940054051 antipsychotic Indole derivatives Drugs 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 229960005110 cerivastatin Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- YGAMIEYKXHAVBP-UHFFFAOYSA-N molecular hydrogen;hydrochloride Chemical compound Cl.[H][H] YGAMIEYKXHAVBP-UHFFFAOYSA-N 0.000 claims 1
- 150000002790 naphthalenes Chemical class 0.000 claims 1
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 150000003222 pyridines Chemical class 0.000 claims 1
- 150000003233 pyrroles Chemical class 0.000 claims 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
Claims (14)
(а) тиенпиридиновое производное формулы I
в которой R обозначает водород или (C1 -C4) алкоксикарбонил,
или одну из его фармацевтически приемлемых солей; и
(б) ингибитор HMG-КоА-редуктазы.1. Pharmaceutical composition containing
(a) thienpyridine derivative of formula I
in which R denotes hydrogen or (C 1 -C 4 ) alkoxycarbonyl,
or one of its pharmaceutically acceptable salts; and
(b) an HMG-CoA reductase inhibitor.
(i) производных нафталина формулы II
в которой R1 и R2 обозначают гидроксильную группу или же вместе образуют атом кислорода;
R3 представляет собой (C1 - C10) алкил, (С3 - С10)циклоалкил, (С2 - С10)алкенил, фенил или фенил (C1 - С3)алкил;
R4 представляет собой водород или метильную или гидроксильную группу;
(ii) фармацевтически приемлемых солей соединений формулы II, в которой R1 и R2 представляют собой гидрокси;
(iii) производных индола формулы III
в которой один из Ro и R' представляет собой структурную группу
в которой Q4 представляет собой атом водорода, хлора или фтора или группу (C1 - C4)алкил, (C1 - C4)алкокси (за исключением трет. бутокси), трифторметил, фенокси или бензилокси,
Q5 представляет собой атом водорода, хлора, фтора или группу фенокси или бензилокси;
Q5a представляет собой атом водорода, хлора, фтора или группу метил, этил, метокси или этокси;
а другой из Ro и R' представляет собой первичную или вторичную группу (С1 - С6)алкил, (C3 - C6) циклоалкил, бензил, 2-фенилэтил или 3-фенилпропил;
Q2 представляет собой атом водорода, фтора, хлора или группу (C1 - C4)алкил, (C3 - C6)циклоалкил, (C1 - C4)алкокси (за исключением трет. бутокси), трифторметил, фенокси или бензилокси;
Q3 представляет собой атом водорода, хлора, фтора или группу (С1 - С3)алкил, (С1 - С3)алкокси, фенокси или бензилокси;
Х представляет собой метилен, этилен или 1,3-пропилен;
Q6 представляет собой атом водорода или группу (С1 - С3)алкил;
при условии, что (1) Q5 и Q5a - водород, если R4 - водород, (2) Q5a - водород, если Q5 - водород, (3) Q4 и Q3 не являются одновременно группой трифторметил, фенокси или бензилокси, (4) Q3 - водород, если и Q2 - водород, (5) Q2 и Q3 не являются одновременно группой трифторметил, фенокси или бензилокси;
(iv) фармацевтически приемлемых сложный эфиров соединений формулы III,
(v) фармацевтически приемлемых солей формулы III,
(vi) δ-лактонов соединений формулы III,
(vii) производных тетразола формулы IV
в которой Q1 и Q1' представляют собой водород, галоген или группу (C1 - C4)алкил, (C1 - C4)алкокси, трифторметил;
Q7, Q7', Q8 и Q8' представляют собой водород, галоген или группу (C1 - C4)алкил, (C1 - C4)алкокси;
Q9 представляет собой водород или группу (C1 - C4)алкил, (C1 - C4)алкоксилалкил или (2-метоксиэтокси)метил;
(viii) фармацевтически приемлемых солей соединений формулы (IV),
(ix) δ-лактонов соединений формулы IV,
(х) пиридиновых производных формулы V
(xi) фармацевтически приемлемых солей соединений формулы (V),
(хii) δ-лактонов соединений формулы V,
(xiii) производных пиррола формулы VI
(xiv) фармацевтически приемлемых солей соединений формулы VI,
(xv) δ-лактонов соединений формулы (VI).7. The composition according to claim 1, characterized in that the HMG-KoA reductase inhibitor is a compound selected among:
(i) naphthalene derivatives of formula II
in which R 1 and R 2 represent a hydroxyl group or together form an oxygen atom;
R 3 is (C 1 - C 10 ) alkyl, (C 3 - C 10 ) cycloalkyl, (C 2 - C 10 ) alkenyl, phenyl or phenyl (C 1 - C 3 ) alkyl;
R 4 represents hydrogen or a methyl or hydroxyl group;
(ii) the pharmaceutically acceptable salts of the compounds of formula II in which R 1 and R 2 are hydroxy;
(iii) indole derivatives of formula III
in which one of R o and R 'is a structural group
in which Q 4 represents a hydrogen atom, chlorine or fluorine or a group (C 1 - C 4 ) alkyl, (C 1 - C 4 ) alkoxy (except tert. butoxy), trifluoromethyl, phenoxy or benzyloxy,
Q 5 represents a hydrogen atom, chlorine, fluorine or a phenoxy or benzyloxy group;
Q 5a represents a hydrogen atom, chlorine, fluorine or a methyl, ethyl, methoxy or ethoxy group;
and another of R o and R ′ is a primary or secondary group (C 1 -C 6 ) alkyl, (C 3 -C 6 ) cycloalkyl, benzyl, 2-phenylethyl or 3-phenylpropyl;
Q 2 is a hydrogen atom, fluorine, chlorine or a group (C 1 - C 4 ) alkyl, (C 3 - C 6 ) cycloalkyl, (C 1 - C 4 ) alkoxy (except tert-butoxy), trifluoromethyl, phenoxy or benzyloxy;
Q 3 represents a hydrogen atom, chlorine, fluorine or a group (C 1 - C 3 ) alkyl, (C 1 - C 3 ) alkoxy, phenoxy or benzyloxy;
X represents methylene, ethylene or 1,3-propylene;
Q 6 represents a hydrogen atom or a group (C 1 - C 3 ) alkyl;
provided that (1) Q 5 and Q 5a is hydrogen, if R 4 is hydrogen, (2) Q 5a is hydrogen, if Q 5 is hydrogen, (3) Q 4 and Q 3 are not simultaneously trifluoromethyl, phenoxy or benzyloxy, (4) Q 3 is hydrogen, if and Q 2 is hydrogen, (5) Q 2 and Q 3 are not at the same time a trifluoromethyl, phenoxy or benzyloxy group;
(iv) pharmaceutically acceptable esters of compounds of formula III,
(v) pharmaceutically acceptable salts of formula III,
(vi) δ-lactones of compounds of formula III,
(vii) tetrazole derivatives of formula IV
in which Q 1 and Q 1 'represent hydrogen, halogen or a group (C 1 - C 4 ) alkyl, (C 1 - C 4 ) alkoxy, trifluoromethyl;
Q 7 , Q 7 ', Q 8 and Q 8 ' represent hydrogen, halogen or a group (C 1 - C 4 ) alkyl, (C 1 - C 4 ) alkoxy;
Q 9 is hydrogen or a group (C 1 - C 4 ) alkyl, (C 1 - C 4 ) alkoxy alkyl or (2-methoxyethoxy) methyl;
(viii) the pharmaceutically acceptable salts of the compounds of formula (IV),
(ix) δ-lactones of compounds of formula IV,
(x) pyridine derivatives of the formula V
(xi) the pharmaceutically acceptable salts of the compounds of formula (V),
(xii) δ-lactones of compounds of formula V,
(xiii) pyrrole derivatives of formula VI
(xiv) the pharmaceutically acceptable salts of the compounds of formula VI,
(xv) δ-lactones of compounds of formula (VI).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9609474A FR2751540B1 (en) | 1996-07-26 | 1996-07-26 | ANTITHROMBOTIC PHARMACEUTICAL COMPOSITION |
FR96/09474 | 1996-07-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU99103623A true RU99103623A (en) | 2001-02-20 |
RU2176504C2 RU2176504C2 (en) | 2001-12-10 |
Family
ID=9494551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU99103623/14A RU2176504C2 (en) | 1996-07-26 | 1997-07-21 | Antiplatelet and antiatherogenic pharmaceutical composition containing thienepyridine derivative and inhibitor of hmg-coa-reductase |
Country Status (35)
Country | Link |
---|---|
US (1) | US6218403B1 (en) |
EP (1) | EP0914124B1 (en) |
JP (1) | JP3553610B2 (en) |
KR (1) | KR100307268B1 (en) |
CN (1) | CN1109547C (en) |
AR (1) | AR008782A1 (en) |
AT (1) | ATE258052T1 (en) |
AU (1) | AU725949B2 (en) |
BR (1) | BR9710560B1 (en) |
CA (1) | CA2261099C (en) |
CZ (1) | CZ294664B6 (en) |
DE (1) | DE69727299T2 (en) |
DK (1) | DK0914124T3 (en) |
EE (1) | EE03853B1 (en) |
ES (1) | ES2214632T3 (en) |
FR (1) | FR2751540B1 (en) |
HK (1) | HK1019405A1 (en) |
HU (1) | HU226245B1 (en) |
ID (1) | ID17774A (en) |
IL (1) | IL128102A0 (en) |
IS (1) | IS2052B (en) |
MY (1) | MY125051A (en) |
NO (1) | NO322894B1 (en) |
NZ (1) | NZ333826A (en) |
PL (1) | PL188739B1 (en) |
PT (1) | PT914124E (en) |
RS (1) | RS49504B (en) |
RU (1) | RU2176504C2 (en) |
SI (1) | SI0914124T1 (en) |
SK (1) | SK284944B6 (en) |
TR (1) | TR199900154T2 (en) |
TW (1) | TW442289B (en) |
UA (1) | UA58518C2 (en) |
WO (1) | WO1998004259A1 (en) |
ZA (1) | ZA976247B (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2769313B1 (en) * | 1997-10-06 | 2000-04-21 | Sanofi Sa | DERIVATIVES OF HYDROXYACETIC ESTERS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS SYNTHESIS INTERMEDIATES |
US7141602B2 (en) * | 1998-09-18 | 2006-11-28 | Lek Pharmaceuticals D.D. | Process for obtaining HMG-CoA reductase inhibitors of high purity |
IL162461A0 (en) * | 2001-12-18 | 2005-11-20 | Teva Pharma | Polymorphs of clopidogrel hydrogensulfate |
US7074928B2 (en) | 2002-01-11 | 2006-07-11 | Teva Pharmaceutical Industries, Ltd. | Polymorphs of clopidogrel hydrogensulfate |
AR040588A1 (en) * | 2002-07-26 | 2005-04-13 | Schering Corp | PHARMACEUTICAL FORMULATION INCLUDING AN INHIBITOR OF CHOLESTEROL ABSORPTION AND AN INHIBITOR OF A HMGCO TO REDUCTASE |
IL166593A0 (en) | 2002-08-02 | 2006-01-15 | Racemization and enantiomer separation of clopidogrel | |
US6800759B2 (en) | 2002-08-02 | 2004-10-05 | Teva Pharmaceutical Industries Ltd. | Racemization and enantiomer separation of clopidogrel |
ATE482698T1 (en) * | 2003-06-18 | 2010-10-15 | Inst Cardiologie De Montreal M | PREVENTING Atrial Fibrillation (AF) WITH THE USE OF STATIN |
US6978908B2 (en) * | 2003-09-15 | 2005-12-27 | Gerber Products Company | Drinking vessel with adjustable handles |
KR100563455B1 (en) * | 2004-04-09 | 2006-03-23 | 한미약품 주식회사 | Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparating same and pharmaceutical composition containing same |
US8580818B2 (en) * | 2005-09-15 | 2013-11-12 | Otsuka Pharmaceutical Co., Ltd. | Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects |
KR101784001B1 (en) * | 2006-04-04 | 2017-10-23 | 케이지 액퀴지션 엘엘씨 | Oral dosage forms including an antiplatelet agent and an acid inhibitor |
US9532945B2 (en) * | 2006-04-04 | 2017-01-03 | Kg Acquisition Llc | Oral dosage forms including an antiplatelet agent and an enterically coated acid inhibitor |
CA2655844A1 (en) * | 2006-08-03 | 2008-02-14 | Teva Pharmaceutical Industries Ltd. | Process for preparing clopidogrel bisulphate |
WO2008060934A2 (en) * | 2006-11-14 | 2008-05-22 | Acusphere, Inc. | Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration |
RU2009140792A (en) * | 2007-04-09 | 2011-05-20 | Юсв Лимитед (In) | NEW STABLE PHARMACEUTICAL COMPOSITIONS BISULPHATE CLOPIDOGEL AND METHOD FOR PRODUCING THEM |
EP2148655B1 (en) * | 2007-04-20 | 2013-02-27 | Wockhardt Limited | Pharmaceutical compositions of clopidogrel |
KR20160033792A (en) * | 2007-04-27 | 2016-03-28 | 사이덱스 파마슈티칼스, 인크. | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use |
WO2010009745A1 (en) * | 2008-07-25 | 2010-01-28 | Pharmathen S.A. | Solid oral dosage form containing anti-platelet agent clopidogrel and method for the preparation thereof |
NZ597510A (en) | 2009-06-25 | 2012-12-21 | Tetra Sia | NOVEL ACETYLSALICYLIC ACID SALTS, the salts are 4-trimethylammoniobutanoate, L-carnitine and meldonium |
RU2461379C2 (en) * | 2010-12-09 | 2012-09-20 | Закрытое акционерное общество "ФАРМ-ЦЕНТР" (ЗАО "ФАРМ-ЦЕНТР") | Pharmaceutical combination possessing antiaggregant and lipid-regulating activities, pharmaceutical composition |
BR112019015107A2 (en) | 2017-01-23 | 2020-03-10 | Dong Wha Pharm. Co., Ltd. | COMPLEX FORMULATION UNDERSTANDING HMG-COA REDUCTASE AND CLOPIDOGREL INHIBITOR |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2003478A1 (en) * | 1988-12-12 | 1990-06-12 | Leonard G. Dennick | Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination |
FR2665440B1 (en) * | 1990-07-31 | 1994-02-04 | Lipha | NOVEL SUBSTITUTED CYCLOALKYLSULFONAMIDES, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM. |
WO1995011898A1 (en) * | 1992-05-12 | 1995-05-04 | Nissan Chemical Industries Ltd. | Condensed pyridine type mevalonolactone intermediate and process for its production |
AU1095695A (en) * | 1993-11-09 | 1995-05-29 | Brigham And Women's Hospital | Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction |
US5945432A (en) * | 1995-12-22 | 1999-08-31 | The University Of Vermont And State Agricultural College | Thrombolytic agents and thienopyridine derivatives in acute stroke |
-
1996
- 1996-07-26 FR FR9609474A patent/FR2751540B1/en not_active Expired - Fee Related
-
1997
- 1997-07-15 ZA ZA976247A patent/ZA976247B/en unknown
- 1997-07-15 TW TW086110010A patent/TW442289B/en not_active IP Right Cessation
- 1997-07-18 AR ARP970103243A patent/AR008782A1/en active IP Right Grant
- 1997-07-21 PL PL97331339A patent/PL188739B1/en unknown
- 1997-07-21 SI SI9730622T patent/SI0914124T1/en unknown
- 1997-07-21 CA CA002261099A patent/CA2261099C/en not_active Expired - Fee Related
- 1997-07-21 EE EEP199900028A patent/EE03853B1/en not_active IP Right Cessation
- 1997-07-21 HU HU9903752A patent/HU226245B1/en not_active IP Right Cessation
- 1997-07-21 TR TR1999/00154T patent/TR199900154T2/en unknown
- 1997-07-21 AU AU38526/97A patent/AU725949B2/en not_active Ceased
- 1997-07-21 DE DE69727299T patent/DE69727299T2/en not_active Expired - Lifetime
- 1997-07-21 UA UA99021085A patent/UA58518C2/en unknown
- 1997-07-21 RU RU99103623/14A patent/RU2176504C2/en not_active IP Right Cessation
- 1997-07-21 US US09/230,299 patent/US6218403B1/en not_active Expired - Lifetime
- 1997-07-21 JP JP50854598A patent/JP3553610B2/en not_active Expired - Fee Related
- 1997-07-21 RS YU3199A patent/RS49504B/en unknown
- 1997-07-21 BR BRPI9710560-0B1A patent/BR9710560B1/en not_active IP Right Cessation
- 1997-07-21 EP EP97935593A patent/EP0914124B1/en not_active Expired - Lifetime
- 1997-07-21 WO PCT/FR1997/001353 patent/WO1998004259A1/en active IP Right Grant
- 1997-07-21 IL IL12810297A patent/IL128102A0/en not_active IP Right Cessation
- 1997-07-21 PT PT97935593T patent/PT914124E/en unknown
- 1997-07-21 NZ NZ333826A patent/NZ333826A/en not_active IP Right Cessation
- 1997-07-21 CN CN97197539A patent/CN1109547C/en not_active Expired - Fee Related
- 1997-07-21 SK SK78-99A patent/SK284944B6/en not_active IP Right Cessation
- 1997-07-21 AT AT97935593T patent/ATE258052T1/en active
- 1997-07-21 ES ES97935593T patent/ES2214632T3/en not_active Expired - Lifetime
- 1997-07-21 CZ CZ1999176A patent/CZ294664B6/en not_active IP Right Cessation
- 1997-07-21 DK DK97935593T patent/DK0914124T3/en active
- 1997-07-24 ID IDP972577A patent/ID17774A/en unknown
- 1997-07-25 MY MYPI97003383A patent/MY125051A/en unknown
-
1999
- 1999-01-22 IS IS4951A patent/IS2052B/en unknown
- 1999-01-22 KR KR1019997000501A patent/KR100307268B1/en not_active IP Right Cessation
- 1999-01-25 NO NO19990321A patent/NO322894B1/en not_active IP Right Cessation
- 1999-11-01 HK HK99104578A patent/HK1019405A1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU99103623A (en) | ANTI-THROMBOTIC AND ANTI-ATEROGENIC PHARMACEUTICAL COMPOSITION CONTAINING TIENPYRIDINE DERIVATIVE AND HMG-COA-REDUCTASE INHIBITOR | |
RU2333199C2 (en) | Diphenylazetidinone derivatives, methods for obtaining same, pharmaceutical compositions and combinations of said derivatives and application thereof in cholesterol absorption inhibition | |
JP4188826B2 (en) | Method for producing calcium salt type statin | |
BG105559A (en) | STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR | |
AU601981B2 (en) | Trans- (2-(3 or 4-carboxamido-substituted pyrrol-1-yl) alkyl)-4-hydroxypyran-2-one inhibitors of cholesterol synthesis | |
US20060211761A1 (en) | Hmg-coa-reductase inhibitors | |
JPH08291082A (en) | Composition for prophylaxis of secondary cardioattack | |
MXPA02012415A (en) | HMG-CoA REDUCTASE INHIBITORS AND METHOD. | |
LU91162I2 (en) | Aloxi-Palonosetrone and its pharmaceutically acceptable derivatives. | |
RU2002103603A (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING An HMG REDUCASE INHIBITOR | |
ES2194202T3 (en) | POLYMORPH COMPOUNDS. | |
JP2002501887A5 (en) | Use of a plasma triglyceride level lowering agent for the manufacture of a medicament for the treatment of Alzheimer's disease | |
EA200700875A1 (en) | DERIVATIVES OF 7- (2H-PYRAZOL-3-IL) -3,5-DIHYDROXYHEPTANIC ACID AS HMG CO-A INHIBITORS REDUCTION FOR LIPIDEMIC TREATMENT | |
DK1200385T3 (en) | Crystals of sodium salt of pravastatin | |
RU2004139029A (en) | APPLICATION OF SUBSTITUTED CYANOPYRROLIDINES AND THEIR COMBINED DRUGS FOR THE TREATMENT OF HYPERLIPIDEMIA AND ASSOCIATED DISEASES | |
ES2029829T3 (en) | A PROCEDURE FOR THE PREPARATION OF ANTI-HYPERCHOLESTEROLEMIC COMPOUNDS. | |
CA2344053A1 (en) | Composition containing cinnamic acid derivatives for preventing or treating elevated blood lipid level-related diseases | |
HK1044955A1 (en) | Heterocyclic compounds, intermediates thereof and elastase inhibitors. | |
JP2007512347A5 (en) | ||
US7078430B2 (en) | HMG CoA-reductase inhibitors | |
RU2380360C2 (en) | Diphenylazetidinone derivatives having inhibitory activity towards cholesterol absorption | |
WO2005014541A1 (en) | Novel antihypercholesterolemic compound | |
TH11684B (en) | Stable pharmaceutical mixtures containing HMG-CoA reductase inhibitors. | |
CA2430760A1 (en) | Antilipemic agents | |
WO2005042483A1 (en) | [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-((1-methylethyl) -3-phenyl-4-[(phenylamino) carbonyl]- 1h-pyrrole-1-heptanoic acid iron salt |